This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jackson, S. R. Articles by Shay, J. W. Search for Related Content PubMed PubMed Citation Articles by Jackson, S. R. Articles by Shay, J. W.

Antiadhesive Effects of GRN163L—An Oligonucleotide N3'P5' Thio-Phosphoramidate Targeting Telomerase

Departments of ¹ Cell Biology and ² Pharmacology and ³ Harold Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas; ⁴ Department of Biochemistry, Faculty of Medicine, University of Hacettepe, Ankara, Turkey; and ⁵ Geron Corporation, Menlo Park, California

Requests for reprints: Jerry W. Shay, Department of Cell Biology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9039. Phone: 214-648-3282; Fax: 214-648-8694; E-mail: jerry.shay{at}utsouthwestern.edu.

We determined previously that a novel human telomerase RNA (hTR) antagonist, GRN163L, inhibited the tumorigenic potential of A549-luciferase (A549-luc) lung cancer cells in vitro and in vivo. Further studies revealed that A549-luc cells were also morphologically altered by GRN163L. A549-luc cells treated before cell attachment with a single dose of GRN163L only weakly attached to the substrate and remained rounded, whereas control mismatch-treated cells exhibited typical epitheloid appearance and adhesion properties. These morphologic changes were independent of hTR expression and telomerase inhibition and were unrelated to telomere length. This effect is dependent on the molecular properties of the lipid moiety, the phosphorothioate backbone, and the presence of triplet-G sequences within the GRN163L structure. Altered adhesion was manifested by a 50% reduction in rapid cellular attachment and a 3-fold decrease in total cell spreading surface area. Administration of a single dose of GRN163L (15 mg/kg) at the time of cell inoculation, using an in vivo model of lung cancer metastasis, resulted in significant reductions in tumor burden at days 13, 20, and 27 of tumor progression. Thus, the potent antimetastatic effects of GRN163L may be related, in part, to the antiadhesive effects of this novel cancer therapeutic conferred via specific structural determinants and that these effects are independent of telomerase inhibition or telomere shortening. [Cancer Res 2007;67(3):1121–9]

This article has been cited by other articles:

				C. Leonetti, M. Scarsella, G. Riggio, A. Rizzo, E. Salvati, M. D'Incalci, L. Staszewsky, R. Frapolli, M. F. Stevens, A. Stoppacciaro, et al. G-Quadruplex Ligand RHPS4 Potentiates the Antitumor Activity of Camptothecins in Preclinical Models of Solid Tumors Clin. Cancer Res., November 15, 2008; 14(22): 7284 - 7291. [Abstract] [Full Text] [PDF]

				M. Agarwal, S. Pandita, C. R. Hunt, A. Gupta, X. Yue, S. Khan, R. K. Pandita, D. Pratt, J. W. Shay, J.-S. A. Taylor, et al. Inhibition of Telomerase Activity Enhances Hyperthermia-Mediated Radiosensitization Cancer Res., May 1, 2008; 68(9): 3370 - 3378. [Abstract] [Full Text] [PDF]

				P. A. Bunn Jr., E. B. Haura, and J. V. Heymach Emerging Therapies for Non-small Cell Lung Cancer ASCO Educational Book, January 1, 2008; 2008(1): e5 - e14. [Abstract] [Full Text] [PDF]